Study on the Efficacy and Safety of MA-BUCY2 Conditioning in High-risk AML Patients Underwent Haplo-HSCT

Xi'an Jiaotong University

Status: Not yet enrolling

Conditions: Haploidentical Stem Cell Transplantation; Conditioning

Treatments: Drug: MA-BUCY2; Drug: BUCY2

Study type: Interventional

Funder types: Other

Identifiers

NCT05814731

XJTU1AF2022SJ-XK005

Details and patient eligibility

About

According to the 2022 ELN guidelines patients with high-risk acute myeloid leukemia were randomly divided into MA-BUCY2 conditioning group and BuCy2 conditioning group，to evaluate the efficacy and safety of two conditioning regimens in haploidentical hematopoietic stem cell transplantation.

Full description

High risk acute myeloid leukemia patients were randomly divided into two groups before conditioning of haploidentical hematopoietic stem cell transplantation.The control group will use the BUCY2 conditioning，and the experimental group will use mitoxantrone liposome combined with BUCY2 for conditioning. After transplantation，we will observe the difference of one year relapse rates between two goups，also the adverse reactions of conditioning，GVHD，OS and PFS of the patients in two groups also been observed.

Enrollment: 264 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Meet the diagnostic criteria of 2022 ELN guidelines for high-risk acute myeloid leukemia;
• Patients with allogeneic stem cell transplantation indications;
• Age 18-60 (including upper and lower limits) ;
• No gender limit;
• ECOG score 0~2 points;
• Flow MRD was negative before transplantation;
• The organ function level must meet the following requirements: a) Liver: aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 3 times the upper limit of normal value (ULN), Total bilirubin (TBIL) ≤ 1.5 × ULN； b) Kidney: blood creatinine ≤ 1.5 × ULN； c) Coagulation function: international normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN； d) Normal cardiac function: that is, the ECG is normal or abnormal without clinical significance, and the left ventricular ejection fraction (LVEF) is greater than 60 or myocardial zymogram CK-MB is normal, pro-BNP is less than 900 pg/ml;
• The results of serum pregnancy test of female subjects with reproductive ability must be negative before the first use of the test drug;

Exclusion criteria

• Previously received doxorubicin or other anthracycline drugs, and the total cumulative dose of doxorubicin was more than 360 mg/m2;

• Hypersensitivity to any study drug or its components;

• Cardiac function and disease meet one of the following conditions:

  1. Long QTc syndrome or QTc interval>480 ms;
  2. Complete left bundle branch block, II or III degree atrioventricular block;
  3. Serious and uncontrolled arrhythmia requiring drug treatment;
  4. American New York Heart Association rating ≥ III;
  5. Cardiac ejection fraction (LVEF) is less than 60%;
  6. History of myocardial infarction, unstable angina pectoris, severe unstable ventricular arrhythmia or He has any arrhythmia requiring treatment, clinical history of serious pericardial disease, or acute ischemia or activity ECG evidence of abnormal conduction system.;\

• Active infection of hepatitis B and hepatitis C;

• Human immunodeficiency virus (HIV) infection;

• Patients with other malignant tumors;

• Pregnant and lactating women and patients of childbearing age who are unwilling to take contraceptive measures;

• Have a history of abuse of drugs;

• History of mental illness or cognitive impairment; .Other researchers judged that it was not suitable for this study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

264 participants in 2 patient groups

MA-BUCY2

Experimental group

Description:

Mitoxantrone liposome 20mg/m2，ivgtt，d-11 ；Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2；

Treatment:

Drug: MA-BUCY2

BUCY2

Active Comparator group

Description:

Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2；

Treatment:

Drug: BUCY2